Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Non-Current Debt (2016 - 2022)

Sonoma Pharmaceuticals has reported Non-Current Debt over the past 11 years, most recently at $15000.0 for Q4 2022.

  • For Q4 2022, Non-Current Debt changed N/A year-over-year to $15000.0; the TTM value through Dec 2022 reached $15000.0, changed N/A, while the annual FY2021 figure was $1.3 million, N/A changed from the prior year.
  • Non-Current Debt for Q4 2022 was $15000.0 at Sonoma Pharmaceuticals, roughly flat from $15000.0 in the prior quarter.
  • Over five years, Non-Current Debt peaked at $1.3 million in Q2 2020 and troughed at $12000.0 in Q1 2019.
  • A 5-year average of $449750.0 and a median of $27000.0 in 2018 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: fell 28.89% in 2018 and later tumbled 62.5% in 2019.
  • Year by year, Non-Current Debt stood at $14000.0 in 2018, then decreased by 14.29% to $12000.0 in 2019, then soared by 10816.67% to $1.3 million in 2020, then changed by 0.0% to $1.3 million in 2021, then tumbled by 98.85% to $15000.0 in 2022.
  • Business Quant data shows Non-Current Debt for SNOA at $15000.0 in Q4 2022, $15000.0 in Q3 2022, and $15000.0 in Q2 2022.